Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Annexon Biosciences
< Previous
1
2
Next >
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases
January 07, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
December 20, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
December 20, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway
December 20, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
December 18, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 22, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
November 13, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference
November 09, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy
October 24, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
October 18, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)
October 10, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference
September 19, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
September 18, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
August 07, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy
July 30, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
July 27, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
July 24, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Topline Data from ARCHER Phase 2 Trial of ANX007 in Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation of Visual Function
May 24, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
May 08, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
March 06, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference
February 27, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
February 16, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
January 08, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio
January 06, 2023
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.